NASHVILLE, Tenn., Nov. 1, 2012 /PRNewswire/ -- Cumberland Pharmaceuticals Inc. (NASDAQ: CPIX), a specialty pharmaceutical company focused on hospital acute care and gastroenterology markets, today announced third quarter 2012 financial results.
Net Revenues: For the three months ended September 30, 2012, net revenues were $12.5 million, compared to $13.1 million in the prior year period. Prior year revenues were boosted by an increase in Acetadote® volume due to shortages of competitive products.
For the nine months ended September 30, 2012, net revenues were $35.2 million compared with $38.1 million for the nine months ended September 30, 2011.
Operating Expenses: Total operating expenses for the three months ended September 30, 2012, were $9.6 million compared with $10.0 million for the prior year period. This decrease was driven by lower selling and marketing expenses associated with our new commercial strategy, partially offset by an increase in R&D expenses.
For the nine months ended September 30, 2012, total operating expenses were $29.6 million, compared to $30.0 million for the nine months ended September 30, 2011.
Net Income: Net income attributable to common shareholders for the three months ended September 30, 2012, was $1.9 million, or $0.10 per diluted share, up 11% from $0.09 per diluted share for the prior year period.
For the nine months ended September 30, 2012, net income attributable to common shareholders was $4.0 million, or $0.20 per diluted share, compared with $4.7 million, or $0.23 per diluted share, for the same period in 2011.
Cash Flow: For the nine months ended September 30, 2012, operating cash flows were $5.1 million, compared to $7.7 million for the nine months ended September 30, 2011.
Balance Sheet: As of September 30, 2012, Cumberland had total assets of $96.9 million. Cash and securities as of September 30, 2012 were $69.4 million, with approximately $50.8 million in cash and equivalents and $18.6 million in marketable securities.
"We continue to remain in a strong financial position with three marketed products, attractive margins and continued double digit earnings growth," said A.J. Kazimi, Chief Executive Officer of Cumberland Pharmaceuticals. "We achieved another quarter of steady financial results and we remain on track to hit our 2012 guidance."
Company Highlights Caldolor®
In September 2012, Cumberland announced the top-line results from a clinical pediatric pain study evaluating the safety and analgesic efficacy of Caldolor® (ibuprofen) Injection in treating pain in tonsillectomy patients ranging from 6 to 16 years old.
When administered prior to surgery, Caldolor use was associated with a statistically significant reduction in the number of post-operative narcotic doses required in patients in the efficacy evaluable population. There were also consistent trends toward reduction in pain scores and the incidence of nausea and vomiting in patients receiving Caldolor. Importantly, no safety concerns were observed during this study.
This study, in combination with the ongoing work to evaluate the treatment of fever in children, will be used to pursue a pediatric indication for Caldolor.
Conference Call and WebcastA conference call and live Internet webcast will be held on Thursday, November 1, 2012, at 4:30 p.m. Eastern Time to discuss the Company's third quarter 2012 financial results. To participate in the call, please dial 877-303-1298 (for U.S. callers) or 253-237-1032 (for international callers). A rebroadcast of the teleconference will be available for one week and can be accessed by dialing 855-859-2056 (for U.S. callers) or 404-537-3406 (for international callers). The Conference ID for the rebroadcast is 50483291. The live webcast and rebroadcast can be accessed via Cumberland's website at http://investor.shareholder.com/cpix/events.cfm.
About Cumberland PharmaceuticalsCumberland Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the acquisition, development and commercialization of branded prescription products. The Company's primary target markets include hospital acute care and gastroenterology. Cumberland's marketed products include Acetadote® (acetylcysteine) Injection, for the treatment of acetaminophen poisoning, Caldolor® (ibuprofen) Injection, the first injectable treatment for pain and fever approved in the United States, and Kristalose® (lactulose) for Oral Solution, a prescription laxative. Cumberland is dedicated to providing innovative products that improve quality of care for patients. For more information, please visit the Company's website at www.cumberlandpharma.com.
About AcetadoteAcetadote, administered intravenously within 8 to 10 hours after ingestion of a potentially hepatotoxic quantity of acetaminophen, is indicated to prevent or lessen hepatic injury. Used in the emergency department, Acetadote is the only injectable product approved in the United States to treat overdose of acetaminophen, a common ingredient in many over-the-counter medications. Acetadote is contraindicated in patients with hypersensitivity or previous anaphylactoid reactions to acetylcysteine or any components of the preparation. Serious anaphylactoid reactions, including death in a patient with asthma, have been reported in patients administered acetylcysteine intravenously. Acetadote should be used with caution in patients with asthma or where there is a history of bronchospasm. The total volume administered should be adjusted for patients weighing less than 40 kg and for those requiring fluid restriction. To avoid fluid overload, the volume of diluent should be reduced as needed. If volume is not adjusted fluid overload can occur, potentially resulting in hyponatremia, seizure and death. For full prescribing information, visit www.acetadote.net.
About CaldolorCaldolor is indicated for the management of mild to moderate pain, for management of moderate to severe pain as an adjunct to opioid analgesics, and for the reduction of fever in adults. It was the first FDA-approved intravenous therapy for fever. Caldolor is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, patients with asthma, urticarial, or allergic type reactions after taking aspirin or other NSAIDs. Caldolor is contraindicated for use during the peri-operative period in the setting of coronary artery bypass graft (CABG) surgery. Caldolor should be used with caution in patients with prior history of ulcer disease or GI bleeding, in patients with fluid retention or heart failure, in the elderly, those with renal impairment, heart failure, liver impairment, and those taking diuretics or ACE inhibitors. Blood pressure should be monitored during treatment with Caldolor. For full prescribing information, including boxed warning, visit www.caldolor.com.
About KristaloseKristalose is indicated for the treatment of acute and chronic constipation. It is a unique, proprietary, crystalline form of lactulose, with no restrictions on length of therapy or patient age. Initial dosing may produce flatulence and intestinal cramps, which are usually transient. Excessive dosage can lead to diarrhea with potential complications such as loss of fluids, hypokalemia and hypernatremia. Nausea and vomiting have been reported. Use with caution in diabetics. Kristalose is contraindicated in patients who require a low-galactose diet. Elderly, debilitated patients who receive lactulose for more than six months should have serum electrolytes (potassium, chloride, carbon dioxide) measured periodically. For full prescribing information, visit www.kristalose.com.
Forward-Looking StatementsThis press release contains forward-looking statements, which are subject to certain risks and reflect Cumberland's current views on future events based on what it believes are reasonable assumptions. No assurance can be given that these events will occur. As with any business, all phases of Cumberland's operations are subject to factors outside of its control, and any one or combination of these factors could materially affect Cumberland's results of operations. These factors include market conditions, competition, an inability of manufacturers to produce Cumberland's products on a timely basis or failure of manufacturers to comply with regulations applicable to pharmaceutical manufacturers, maintaining an effective sales and marketing infrastructure and other factors discussed in the Company's Form 10-K filed with the SEC on March 7, 2012 and Form 10-Q for the quarter ended March 31, 2012 to be filed with the SEC on or before May 15, 2012. There can be no assurance that results anticipated by the Company will be realized or that they will have the expected effects. Readers are cautioned not to place undue reliance on forward-looking statements, which speak only as of the date hereof. The Company does not undertake any obligation to publicly revise these statements to reflect events after the date hereof.
CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Balance Sheets(Unaudited)September 30,December 31,20122011ASSETSCurrent assets:Cash and cash equivalents
18,559,476-Accounts receivable, net of allowances
7,511,6415,774,694Other current assets
4,451,7863,851,337Total current assets
86,791,92987,308,067Property and equipment, net
1,120,5911,119,339Intangible assets, net
95,518,316LIABILITIES AND EQUITYCurrent liabilities:Accounts payable
,513,548Other current liabilities
4,429,9045,086,400Total current liabilities
8,658,1346,599,948Revolving line of credit
4,359,9514,859,951Other long-term liabilities
13,601,87512,683,047Commitments and contingenciesEquity:Shareholders' equity:Common stock - no par value; 100,000,000 shares authorized;19,173,846 and 20,020,535 shares issued and outstandingas of September 30, 2012 and December 31, 2011, respectively
16,693,65412,656,662Total shareholders' equity
83,331,92182,835,269Total liabilities and equity
95,518,316 CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Net and Comprehensive Income(Unaudited)Three months ended September 30,Nine months ended September 30,2012201120122011Net revenues
38,110,946Costs and expenses:Cost of products sold
921,8621,341,2562,873,4173,411,354Selling and marketing
4,914,5515,060,54615,387,06816,253,574Research and development
1,696,5921,233,0254,653,9573,269,746General and administrative
1,901,9862,149,3646,331,1096,522,874Amortization of productlicense right
117,565171,727344,211515,180Total costs and expenses
(17,222)(33,390)(56,369)(329,037)Income before income taxes
3,069,6603,117,4295,764,8147,956,809Income tax expense
1,862,1561,838,9574,012,2514,718,388Net loss at subsidiary attributable tononcontrolling interests
7,3388,45524,74127,803Net income attributable tocommon shareholders
4,746,191Earnings per share attributable to common shareholders- basic
.23Weighted-average shares outstanding- basic
19,670,74120,534,64719,969,05120,657,567 CUMBERLAND PHARMACEUTICALS INC. AND SUBSIDIARIESCondensed Consolidated Statements of Cash Flows(Unaudited)Nine Months Ended September 30,20122011Cash flows from operating activities:Net income
4,718,388Adjustments to reconcile net income to net cash flows fromoperating activities:Depreciation and amortization expense
664,369801,483Stock-based compensation - nonemployees
101,038119,313Stock-based compensation - employees
455,666467,850Excess tax benefit derived from exercise of stock options
(2,176,222)(2,657,259)Noncash interest expense
16,050131,469Net unrealized investment gains
(99,286)-Net changes in assets and liabilities affectingoperating activities:Accounts receivable
(1,736,947)809,243Other current assets and other assets
(1,228,382)(1,240,700)Accounts payable and other accrued liabilities
4,178,7083,911,450Other long-term liabilities
(655,201)(9,262)Net cash provided by operating activities
5,147,4797,692,058Cash flows from investing activities:Additions to property and equipment
(293,693)(241,885)Purchases of marketable securities
(18,849,492)-Proceeds from marketable securities
389,302-Additions to intangibles
(1,621,100)(140,356)Net cash used in investment activities
(20,374,983)(382,241)Cash flows from financing activities:Principal payments on note payable
-(5,333,333)Net (repayments) borrowings on line of credit
(500,000)2,750,000Proceeds from exercise of stock options
580,101681,634Excess tax benefit derived from exercise of stock options
2,176,2222,657,259Repurchase of common shares
(6,826,394)(2,884,540)Net cash used in financing activities
(4,570,071)(2,128,980)Net (decrease) increase in cash and cash equivalents
(19,797,575)5,180,837Cash and cash equivalents at beginning of period
70,599,14665,893,970Cash and cash equivalents at end of period
71,074,807Supplemental disclosure of cash flow information:Non-cash investing and financing activities:Net change in unpaid additions to intangibles, propertyand equipment
|SOURCE Cumberland Pharmaceuticals Inc.|
Copyright©2012 PR Newswire.
All rights reserved